Johnson & Johnson is withdrawing the Linx Reflux Management System from markets outside the U.S., citing a commercial decision unrelated to the device’s safety or efficacy, Bloomberg’s Ashleigh Furlong reports. The withdrawal of the Linx device will deprive patients of a treatment option for gastroesophageal reflux disease, and will also impact lung transplant patients, who often require treatment for GERD to prevent rejection of the transplanted organ, with the Linx device having been used for this purpose in some cases, according to the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Kenvue Stock (KVUE) Pops, Defying Trump’s Claim Linking Tylenol to Autism
- Guggenheim upgrades Johnson & Johnson on growth post Stelara expiry
- Closing Bell Movers: ACM Research up 5% after joining S&P SmallCap 600
- Johnson & Johnson upgraded to Buy from Neutral at Guggenheim
- Kenvue Stock (KVUE) Under Watch as Trump Team Eyes Tylenol–Autism Link